1. Goulston A. West Indian cane sugar in the treatment of certain forms of heart disease. Br Med J693-695, 1912
2.
2. Heberden W. Some account of a disorder of the breast. Medical Transactions. Royal College of Physicians. Vol. 2. London, 1772
3.
3. Major RH. In Major RH, ed:.Classic Descriptions of Disease. Charles C Thomas, Illinois, 1945
4.
4. White PD. Heart Disease, Third Edition. Macmillan Company, New York, 1944
5.
5. Home E. Life of John Hunter. In Hunter J, ed: Treatise on the Blood, Inflammation and Gun-shot Wounds. Philadelphia, 1796
6.
6. Snellen HA. History of Cardiology. Donker Academic Publications, Rotterdam, 1984
7.
7. Bing RJ. In Bing RJ, ed. Cardiology: The Evolution of the Science and the Art. Harwood Academic Publishers, USA, 1992
8.
8. Bums A. Observations on some of the most frequent and important diseases of the heart; on aneurysm of the thoracic aorta; on preternatural pulsation in the epigastric region; and on the unusual origin and distribution of some of the large arteries of the human body. Bryce, Edinburgh, 1809
9.
9. Virchow R. Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre. Hischwald, Berlin, p 122-122, 1858
10.
10. Lewis T. Diseases of the Heart. Macmillan, London, 1933
11.
11. Lewis T, Pickering GW, Rothschild P. Observations upon muscular pain in intermittent claudication. Heart15:359-383, 1931
12.
12. Fleming PR. A Short History of Cardiology. Rodopi, Amsterdam, 1997
13.
13. Meier B. The first patient to undergo coronary angioplasty-23-year follow-up. N Engl J Med344:144-145, 2001
14.
14. Brunton TL. On the use of nitrite of amyl in angina pectoris. Lancet11:97-98, 1867
15.
15. Black J. Foreword. In Cruickshank JM, Prichard BNC, eds: Beta-Blockers in Clinical Practice. Churchill Livingstone, Edinburgh, 1987
16.
16. Black JW, Stephenson JS. Pharmacology of a new adrenergic 3-receptor-blocking compound (Nethalide). Lancet2:311-314, 1962
17.
17. Black JW, Crowther AF, Shanks RG, et al. A new adrenergic betareceptor antagonist. Lancet13:1080-1081, 1964
18.
18. Haas H, Haertfelder G. [(N-methyl-N-homoveratryl)-gamma-aminopropyl]-3,4-dimethoxyphenyl-acetonit rile, a substance with coronary vasodilating properties]. Arzneimittelforschung12:549-558, 1962
19.
19. Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In Harris P, Opie LH, eds: Calcium and the Heart. Academic Press, New York, pp 135-188, 1971
20.
20. Singh BN, Chew CY, Josephson MA, et al. Part I: Pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil. Am J Cardiol50:886-893, 1982
21.
21. Loos A, Kaltenbach M. The effect of nifedipine (BAY a 1040) on the stress electrocardiogram of angina pectoris patients. Arzneimittel-Forschung (Drug Research)22:358-358, 1972
22.
22. Imai S. Effects of coronary vasodilators on the large conductance artery as compared with those on the small resistive artery and arterioles. Jpn Circ J40:472-472, 1976
23.
23. Bing RJ, Siegel A, Ungar I, et al. Metabolism of the human heart. Am J Med16:504-515, 1954
24.
24. Shipp J, Opie L, Challoner D. Fatty acid and glucose metabolism in the perfused heart. Nature189:1018-1019, 1961
25.
25. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet13:785-789, 1963
26.
26. Sodi-Pallares D, Testelli M, Fishelder F. Effects of an intravenous infusion of a potassium-insulin-glucose solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol9:166-181, 1962
27.
27. Owen P, Thomas M, Opie L. Relative changes in freefatty-acid and glucose utilisation by ischaemic myocardium after coronary-artery occlusion. Lancet1:1187-1190, 1969
28.
28. de Leiris J, Opie LH, Lubbe WF. Effects of free fatty acid and glucose on enzyme release in experimental myocardial infarction. Nature253:746-747, 1975
29.
29. Oliver MF, Kurien VA, Greenwood TW. Relation between serum free fatty acids and arrhythmias and death after myocardial infarction. Lancet1:710-715, 1968
30.
30. Opie LH. Effect of fatty acids on contractility and rhythm of the heart. Nature227:1055-1056, 1970
31.
31. Henderson AH, Most AS, Parmley WW, Gorlin R, Sonnenblick EH. Depression of myocardial contractility in rats by free fatty acids during hypoxia. Circ Res26:439-449, 1970
32.
32. Mjos OD. Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J Clin Invest50:1869-1873, 1971
33.
33. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol36:413-459, 1974
34.
34. Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects of contractile function, diastolic compliance, metabolism, and ultrastructure during ischaemia and reperfusion. Circ Res52:515-526, 1983
35.
35. Eberli FR, Weinberg EO, Grice WN, et al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res68:466-481, 1991
36.
36. Cave AC, Ingwall JS, Friedrich J, et al. ATP synthesis during low-flow ischemia. Influence of increased glycolytic substrate. Circulation101:2090-2096, 2000
37.
37. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic perfusion of ischemic hearts. J Pharmacol Exper Ther264:135-144, 1993
38.
38. Stanley WC, Lopaschuk GD, Hall HL, McGormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions potential for pharmacological interventions. Cardiovasc Res33:243-257, 1997
39.
39. Lopaschuk GD, Rebeyka IM, Allard MF. Metabolic modulation. A means to mend a broken heart. Circulation105:140-142, 2002
40.
40. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: Potential mechanisms. Circulation105:1861-1870, 2002
41.
41. Taegtmeyer H. Metabolism-The lost child of cardiology. (Editorial). J Am Coll Cardiol36:1386-1388, 2000
42.
42. Pepine CJ, Schang SJ, Bemiller CR. Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia. Circulation49:887-893, 1974
43.
43. Kennedy JA, Kiosoglous AJ, Murphy GA, et al. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol36:794-801, 2000
44.
44. Renaud JF. Internal pH, Na and Ca regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther1:677-686, 1988
45.
45. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res86:580-588, 2000
46.
46. McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation93:135-142, 1996
